Detailed Coverage

Anthem Biosciences Q1 FY27 Results

Anthem Biosciences reported consolidated revenue of Rs 418.22 crore for the quarter ended June 30, 2026. Consolidated profit stood at Rs 119.94 crore.

Reader Takeaway: Sequential growth in CRDMO segment offers promise; margin pressure is a persistent concern.

What just happened

Anthem Biosciences released its financial results for the first quarter of the fiscal year 2027 (Q1 FY27). The company reported consolidated revenue of Rs 418.22 crore and a consolidated profit of Rs 119.94 crore. On a standalone basis, revenue was Rs 383.84 crore with a profit of Rs 102.01 crore.

The Contract Research and Development Manufacturing Organization (CRDMO) segment was the primary contributor to revenue, generating Rs 340.80 crore. The Speciality Ingredients segment contributed Rs 77.42 crore.

Why this matters

The financial performance indicates continued revenue generation, with the CRDMO segment being the backbone of the company's operations. An unmodified audit opinion from K.P. Rao & Co. provides assurance on the reported financials.

The backstory

The company also approved the allotment of 1,670,909 equity shares under its 'ESOP Scheme 2024'. These approvals followed Board meetings on May 19, 2026, and June 16, 2026.

What changes now

Investors will look at how the company sustains its growth trajectory and manages its segment contributions. The subsidiary, Neoanthem Lifesciences Private Limited, contributed Rs 35.81 crore in revenue before consolidation. The results were reviewed by the Audit Committee and approved by the Board on July 21, 2026.

Risks to watch

Maintaining segment contribution and profit margins in a competitive CRDMO market remains a key area for investors to monitor.

Peer comparison

Information on peer comparison is not available in the provided filing.

Context metrics (time-bound)

Consolidated Revenue (Q1 FY27): Rs 418.22 crore
Consolidated Profit (Q1 FY27): Rs 119.94 crore
Standalone Revenue (Q1 FY27): Rs 383.84 crore
Standalone Profit (Q1 FY27): Rs 102.01 crore
CRDMO Segment Revenue: Rs 340.80 crore
Speciality Ingredients Segment Revenue: Rs 77.42 crore

What to track next

Investors should track the company's ability to maintain its market share in the CRDMO segment and its overall profitability in the upcoming quarters.